Results

Total Results: 518 records

Showing results for "renal".

201. Diabetes-Foot-Ulcer-Amputation-Incidence Research (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/diabetes-foot-ulcer-amputation-incidence_research.pdf
     January 01, 2011 - amputation 2 People with diabetes often experience sev- eral associated medical complications, such as renal … The latter set of ICD-9 codes represents the following microvascular diseases: diabetic renal disease … Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population.

202. X-Rays | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/x-rays?page=0
     July 29, 2016 - Research Protocol Archived June 13, 2013 Troponin Cardiac Marker Interpretation During Renal

203. X-Rays | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/x-rays
     July 29, 2016 - Research Protocol Archived June 13, 2013 Troponin Cardiac Marker Interpretation During Renal

204. Heart Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/heart-diseases?page=2
     January 31, 2012 - Comparative Effectiveness of Antihypertensive Therapies on Cardiovascular Disease Outcomes In End-Stage Renal

205. Heart Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/heart-diseases?page=1
     January 10, 2014 - Research Protocol Archived June 13, 2013 Troponin Cardiac Marker Interpretation During Renal

206. Vascular Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/vascular-diseases?page=1
     February 11, 2014 - Research Protocol Archived June 13, 2013 Troponin Cardiac Marker Interpretation During Renal

207. Vascular Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/vascular-diseases?page=2
     March 05, 2012 - Comparative Effectiveness of Antihypertensive Therapies on Cardiovascular Disease Outcomes In End-Stage Renal

208. Heart Attack | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/heart-attack
     November 14, 2017 - Research Protocol Archived June 13, 2013 Troponin Cardiac Marker Interpretation During Renal

209. Use of Natriuretic Peptide Measurement in the Management of Heart Failure | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/heart-failure-natriuretic-peptide/research-protocol
     December 01, 2019 - specificity and the potential influences of confounders such as age, ethnicity, and comorbidities (including renal … coronary artery disease (CAD), with CAD, other adults at risk of HF without documented HF (diabetes, renal … disease has been used to include or exclude subjects (e.g., acute coronary syndrome (ACS), CAD, Diabetes, Renal … hematocrit, widened QRS interval on 12-lead electrocardiogram, chronic hypotension, resting tachycardia, renal … decreasing hematocrit, widened QRS on 12-lead electrocardiogram, chronic hypotension, resting tachycardia, renal

210. Disposition of Comments for Use of Natriuretic Peptide Measurement in the Management of Heart Failure (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/heart-failure-natriuretic-peptide_disposition-comments.pdf
     November 20, 2013 - Rev 3 disc The decision to emphasize BMI and renal function as potential confounders of the diagnostic … The AHRQ report in 2006 identified both renal function and weight as potential physiological variables … high sensitivity C-reactive protein, N- terminal proBNP, and cardiac troponin T and I in end stage renal … If key data such as heart rhythm, body mass and renal function are not included then the model is not … Should be more emphasis on the key importance of heart rhythm along with adiposity and renal function

211. Ace-Inhibitor-Arb-Update-Surveillance-160328 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-update-surveillance-160328.pdf
     March 28, 2016 - $ vascular$disease$or$events$[including$stroke],$symptomatic$coronary$artery$ disease,$end"stage$renal … $Treatment$of$hypertension$with$renin"angiotensin$ system$inhibitors$and$renal$dysfunction:$a$systematic … $pressure$reduction$in$the$ placebo$arms$of$modern$hypertension$trials:$implications$for$trials$of$renal … $The$composite$primary$outcome$was$the$time$to$death,$end"stage$renal$disease,$or$a$50%$reduction$from … $ACEIs.$$ Lipid&levels,&markers&of& carbohydrate&metabolism/diabetes& control,&&&progression&of&renal

212. Dietary Proteins | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/dietary-proteins?page=3
     August 29, 2011 - Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage Renal

213. Alcohol-Misuse-Drug-Therapy Clinician (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/alcohol-misuse-drug-therapy_clinician.pdf
     February 01, 2016 - Modulates hyperactive glutamatergic n-methyl-d-aspartate receptors Anxiety Diarrhea Vomiting Severe renal … a Dose adjustment for moderate renal impairment.

214. Cancer-Drugs-Utilization Research (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cancer-drugs-utilization_research.pdf
     January 01, 2011 - These data are consistent with the biologic’s indications for advanced renal cell carcinoma and hepatocellular … malignancy of other and unspecified sites (190.x to 199.x), indicative of their labeled use in advanced renal … Clearly, these biologics’ off-label use in renal cell carcinoma, chronic myelogenous leukemia, and metastatic

215. Chronic Kidney Disease Stages 1-3: Screening, Monitoring, and Treatment | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/kidney-disease-medicine/research
     December 01, 2019 - receptor blockers (ARBs) (RR 0.77, 95 percent CI, 0.66 to 0.90) significantly reduced risk of end-stage renal

216. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/high-cholestorol-medications_disposition-comments.pdf
     March 10, 2010 - and consider dose reduction; limit to 10 mg once daily when used in combination with gemfibrozil • Renal … insufficiency statement: Rosuvastatin exposure is not influenced by mild to moderate renal impairment … , exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal … Please edit to reflect dosage adjustment is in patients with severe renal impairment. … Such patients are frail elderly, with small body size, and diminished renal and hepatic function.

217. Disposition of Comments Report for Recurrent Nephrolithiasis in Adults (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/kidney-stone-prevention_disposition-comments.pdf
     July 26, 2012 - direct patient-centered outcome is clinically meaningful kidney damage (e.g. incident end stage renal … disease, progression to stage 4 CKD or worse, developing of acute renal failure requiring hospitalization … incident end stage renal disease, progression to stage 4 CKD or worse, developing of acute renal failure … Peer Reviewer #3 Discussion Using acute renal failure or end stage renal disease as outcomes is impractical … We do not know what causes stones to become detached and/or to pass and most non-obstructing renal

218. Data Points #6: Utilization and cost of anticancer biologic products among Medicare beneficiaries, 2006-2009 | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/cancer-drugs-utilization-cost/research
     December 01, 2019 - Administration (FDA) has labeled peginterferon alfa-2a for use in hepatitis, off-label uses include renal

219. Stroke Prevention in Atrial Fibrillation | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/stroke-atrial-fibrillation/research
     December 01, 2019 - respectively; low strength of evidence for both scores) and that the HAS-BLED (Hypertension, Abnormal renal

220. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/heart-failure-natriuretic-peptide_research-protocol.pdf
     December 20, 2011 - and the potential influences of confounders such as age, ethnicity, and comorbidities (including renal … coronary artery disease (CAD), with CAD, other adults at risk of HF without documented HF (diabetes, renal … has been used to include or exclude subjects (e.g., acute coronary syndrome (ACS), CAD, Diabetes, Renal … hematocrit, widened QRS interval on 12-lead electrocardiogram, chronic hypotension, resting tachycardia, renal … widened QRS interval on 12-lead electrocardiogram, chronic hypotension, resting tachycardia, and renal